We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Dupixent Improves Symptoms and Reduces Inflammatory Cells in Esophageal Disorder
Dupixent Improves Symptoms and Reduces Inflammatory Cells in Esophageal Disorder
Sanofi and Regeneron added another brick to their joint Dupixent franchise with more phase 3 data confirming the antibody’s benefit in eosinophilic esophagitis, a chronic inflammatory disorder that can increase the risk of esophageal cancer.